文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病中的铁状态、成纤维细胞生长因子23与心血管及肾脏结局

Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease.
PubMed 文献 · Kidney Int · 2021-07-30

在3747例慢性肾功能不全队列研究参与者的前瞻性分析中,基于转铁蛋白饱和度和铁蛋白四分位数将铁状态分类,发现铁缺乏、混合性铁缺乏和高铁状态与死亡率、心力衰竭及终末期肾病风险增加相关,且FGF23显著介导铁缺乏相关死亡和心衰风险。

要点

  • 铁缺乏与死亡(HR 1.28)和心衰(HR 1.34)风险独立相关。
  • 混合性铁缺乏与死亡(HR 1.61)和ESKD(HR 1.33)风险相关。
  • 高铁状态与死亡(HR 1.54)、心衰(HR 1.58)和ESKD(HR 1.41)风险相关。

核心结论

  • 慢性肾脏病患者中铁稳态异常与不良心血管和肾脏结局相关。
  • FGF23显著介导铁缺乏相关的死亡和心力衰竭风险。

研究设计与样本

  • 前瞻性分析3747例慢性肾功能不全队列研究参与者。
  • 根据转铁蛋白饱和度和铁蛋白四分位数将铁状态分类。

主要发现

  • 铁缺乏与死亡率(HR 1.28,95%CI 1.04-1.58)和心力衰竭(HR 1.34,95%CI 1.05-1.72)独立相关。
  • 混合性铁缺乏与死亡率(HR 1.61,95%CI 1.27-2.04)和ESKD(HR 1.33,95%CI 1.02-1.73)相关。
  • 高铁状态与死亡率(HR 1.54,95%CI 1.24-1.91)、心力衰竭(HR 1.58,95%CI 1.21-2.05)和ESKD(HR 1.41,95%CI 1.13-1.77)相关。
  • 功能性铁缺乏与任何结局均无显著关联,且无铁状态组与动脉粥样硬化性心血管疾病显著相关。

临床怎么用

  • 在CKD患者中应关注铁状态分类,铁缺乏、混合性铁缺乏和高铁状态提示不良结局风险增加。
  • FGF23可能作为铁缺乏相关心衰和死亡风险的介导因素,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disordered iron and mineral homeostasis are interrelated complications of chronic kidney disease that may influence cardiovascular and kidney outcomes. In a prospective analysis of 3747 participants in the Chronic Renal Insufficiency Cohort Study, we investigated risks of mortality, heart failure, end-stage kidney disease (ESKD), and atherosclerotic cardiovascular disease according to iron status, and tested for mediation by C-terminal fibroblast growth factor 23 (FGF23), hemoglobin and parathyroid hormone. Study participants were agnostically categorized based on quartiles of transferrin saturation and ferritin as "Iron Replete" (27.1% of participants; referent group for all outcomes analyses), "Iron Deficiency" (11.1%), "Functional Iron Deficiency" (7.6%), "Mixed Iron Deficiency" (iron indices between the Iron Deficiency and Functional Iron Deficiency groups; 6.3%), "High Iron" (9.2%), or "Non-Classified" (the remaining 38.8% of participants). In multivariable-adjusted Cox models, Iron Deficiency independently associated with mortality (hazard ratio 1.28, 95% confidence interval 1.04-1.58) and heart failure (1.34, 1.05- 1.72). Mixed Iron Deficiency associated with mortality (1.61, 1.27-2.04) and ESKD (1.33, 1.02-1.73). High Iron associated with mortality (1.54, 1.24-1.91), heart failure (1.58, 1.21-2.05), and ESKD (1.41, 1.13-1.77). Functional Iron Deficiency did not significantly associate with any outcome, and no iron group significantly associated with atherosclerotic cardiovascular disease. Among the candidate mediators, FGF23 most significantly mediated the risks of mortality and heart failure conferred by Iron Deficiency. Thus, alterations in iron homeostasis associated with adverse cardiovascular and kidney outcomes in patients with chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Mehta RC, Cho ME, Cai X, et al. Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int. 2021. PMID: 34339746. doi:10.1016/j.kint.2021.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。